Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications.

ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg (2005) 1.27

Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol (2010) 1.13

Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer (2010) 0.95

What is New on Thyroid Cancer Biomarkers. Biomark Insights (2008) 0.91

Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. Oncotarget (2013) 0.88

Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Indian J Med Paediatr Oncol (2012) 0.82

The CCAAT/enhancer-binding protein beta-2 isoform (CEBPβ-2) upregulates galectin-7 expression in human breast cancer cells. PLoS One (2014) 0.81

Nuclear presence of adhesion-/growth-regulatory galectins in normal/malignant cells of squamous epithelial origin. Histochem Cell Biol (2005) 0.80

Galectin-1, -3, -7 expressions in congenital and acquired pediatric cholesteatomas compared to external auditory canal skin. Clin Exp Otorhinolaryngol (2012) 0.78

Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster. Histochem Cell Biol (2004) 0.77

Advances in cellular therapy for the treatment of thyroid cancer. J Oncol (2010) 0.76

Expression and functions of galectin-7 in human and murine melanomas. PLoS One (2013) 0.75

Clinical significance of galectin-7 in vulvar squamous cell carcinoma. Oncol Lett (2015) 0.75

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46

Galectin-1: a small protein with major functions. Glycobiology (2006) 3.06

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 2.83

Galectins: structure, function and therapeutic potential. Expert Rev Mol Med (2008) 2.61

Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem (2003) 2.27

Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest (2003) 2.18

Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol (2006) 2.14

Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci U S A (2003) 1.94

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol (2008) 1.94

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist (2007) 1.85

Chemical biology of the sugar code. Chembiochem (2004) 1.78

Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis (2008) 1.71

Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation (2003) 1.71

Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta (2007) 1.70

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67

Post mortem examination in the intensive care unit: still useful? Intensive Care Med (2004) 1.66

Acute transient thyroid swelling after fine-needle aspiration biopsy: rare complication of unknown origin. Clin Endocrinol (Oxf) (2011) 1.64

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62

Galectin-3 induces death of Candida species expressing specific beta-1,2-linked mannans. J Immunol (2006) 1.61

3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem (2002) 1.59

Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds. J Biol Chem (2002) 1.58

Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol (2004) 1.57

Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem (2002) 1.53

Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev (2007) 1.50

Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem (2009) 1.50

Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50

Cell culture processes for monoclonal antibody production. MAbs (2010) 1.48

From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci (2011) 1.46

Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells. J Cell Biol (2005) 1.43

Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. J Invest Dermatol (2008) 1.42

Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med (2010) 1.41

Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40

Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer (2002) 1.38

Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37

Galectins and cancer. Biochim Biophys Acta (2002) 1.37

Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res (2004) 1.36

Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med (2004) 1.35

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34

Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34

Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology (2013) 1.33

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30

Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. Biochemistry (2005) 1.29

Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J Immunol (2008) 1.29

Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol (2009) 1.28

Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol (2005) 1.28

Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood (2009) 1.27

The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc. Proc Natl Acad Sci U S A (2005) 1.26

Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci (2009) 1.26

Adjusting the outputs of a classifier to new a priori probabilities: a simple procedure. Neural Comput (2002) 1.26

Cell mechanics using atomic force microscopy-based single-cell compression. Langmuir (2006) 1.26

Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem (2009) 1.25

Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem (2001) 1.25

Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol (2004) 1.24

Role of galectin-3 in human pulmonary fibrosis. Allergol Int (2007) 1.24

Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol (2004) 1.23

Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J Immunol (2007) 1.23

Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol (2004) 1.22

Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol (2012) 1.22

The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia (2007) 1.22

LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. J Immunol (2004) 1.22

Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery (2008) 1.21

Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer (2004) 1.21

The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21

Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum (2003) 1.20

2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem (2007) 1.20

Regulation of cellular homeostasis by galectins. Glycoconj J (2004) 1.20

4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia (2007) 1.18

Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther (2006) 1.17

Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem (2008) 1.16

Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A (2009) 1.16

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15

Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 1.15

The sugar code: functional lectinomics. Biochim Biophys Acta (2002) 1.14

Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia (2006) 1.14

Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol (2002) 1.14